Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juergen Mack is active.

Publication


Featured researches published by Juergen Mack.


Bioorganic & Medicinal Chemistry Letters | 2011

Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.

Joerg Kley; Juergen Mack; Bradford S. Hamilton; Stefan Scheuerer; Norbert Redemann

Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats.


Archive | 2000

Fap-activated anti-tumor compounds

Raymond A. Firestone; Wolfgang J. Rettig; Martin Lenter; Stefan Peters; Pilar Garin-Chesa; Juergen Mack; Dietmar Leipert; John Edward Park; Leila A. Telan


Archive | 2009

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

Roland Pfau; Kirsten Arndt; Henri Doods; Norbert Hauel; Klaus Klinder; Raimund Kuelzer; Juergen Mack; Henning Priepke; Dirk Stenkamp


Archive | 2005

Use of substituted pyrimido[5,4-D]pyrimidines for the treatment of respiratory diseases

Peter Nickolaus; Christopher Montague J. Meade; Domnic Martyres; Juergen Mack; Birgit Jung; Horst Dollinger; Georg Dahmann


Archive | 2005

Use of substituted pteridines for the treatment of respiratory diseases

Peter Nickolaus; Christopher Montague J. Meade; Domnic Martyres; Juergen Mack; Birgit Jung; Horst Dollinger; Georg Dahmann


Archive | 2005

Substituted pteridines for the treatment of inflammatory diseases

Horst Dollinger; Juergen Mack; Domnic Martyres; Birgit Jung; Peter Nickolaus


Archive | 2005

Use of substituted pteridines for the treatment of diseases of the respiratory tract

Peter Nickolaus; Christopher John Montague Meade; Horst Dollinger; Juergen Mack; Georg Dahmann; Domnic Martyres; Birgit Jung


Archive | 2005

Novel, sustained-action beta-2-agonists and their use as medicaments

Thierry Bouyssou; Christoph Hoenke; Ingo Konetzki; Juergen Mack; Andreas Schnapp


Archive | 2006

Alpha-Carbolines as CDK-1 inhibitors

Peter Sennhenn; Andreas Mantoulidis; Matthias Treu; Ulrike Tontsch-Grunt; Walter Spevak; Darryl Mcconnell; Andreas Schoop; Ralph Brueckner; Albrecht Jacobi; Ulrich Guertler; Gisela Schnapp; Christian Klein; Frank Himmelsbach; Alexander Pautsch; Bodo Betzemeier; Lars Herfurth; Juergen Mack; Dieter Wiedenmayer; Gerd Bader; Ulrich Reiser


Archive | 2005

Long acting beta-2-agonists and their use as medicaments

Thierry Bouyssou; Ingo Konetzki; Philipp Lustenberger; Juergen Mack; Andreas Schnapp; Dieter Wiedenmayer; Christoph Hoenke; Klaus Rudolf

Collaboration


Dive into the Juergen Mack's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge